These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3211176)

  • 1. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
    Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A
    Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.
    Bittkau S; Przuntek H
    J Neural Transm Suppl; 1988; 27():35-54. PubMed ID: 3165438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Carta A; Ryatt J; Quinn N; Jenner P; Marsden CD; Agnoli A
    Mov Disord; 1992; 7(3):249-56. PubMed ID: 1620143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
    Obeso JA; Luquin MR; Martínez Lage JM
    Ann Neurol; 1986 Jan; 19(1):31-5. PubMed ID: 3947037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease.
    Rabey JM; Streifler M; Treves T; Korczyn AD
    Adv Neurol; 1990; 53():451-5. PubMed ID: 2122652
    [No Abstract]   [Full Text] [Related]  

  • 10. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of lisuride in the "on-off" phenomena due to L-dopa].
    Piccinin GL; Piccirilli M; Rizzo PA; Agostini L
    Clin Ter; 1983 Mar; 104(6):469-71. PubMed ID: 6851447
    [No Abstract]   [Full Text] [Related]  

  • 12. A study on the effect and tolerance of lisuride on Parkinson's disease.
    Bayülkem K; Erişir K; Tuncel A; Bayülkem B
    Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients.
    Rabey JM; Treves T; Streifler M; Korczyn AD
    Adv Neurol; 1987; 45():569-72. PubMed ID: 3825734
    [No Abstract]   [Full Text] [Related]  

  • 17. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisuride infusion pump for Parkinson's disease.
    Lancet; 1986 Aug; 2(8502):348-9. PubMed ID: 2874360
    [No Abstract]   [Full Text] [Related]  

  • 19. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
    Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
    J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
    Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN
    Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.